KYMR logo

KYMR
Kymera Therapeutics Inc

846
Mkt Cap
$6.49B
Volume
549,371.00
52W High
$103.00
52W Low
$28.06
PE Ratio
-22.09
KYMR Fundamentals
Price
$78.89
Prev Close
$80.61
Open
$79.76
50D MA
$83.20
Beta
1.57
Avg. Volume
510,795.41
EPS (Annual)
-$3.69
P/B
4.21
Rev/Employee
$164,752.10
$5,808.19
Loading...
Loading...
News
all
press releases
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...
News Placeholder
More News
News Placeholder
Canaccord Genuity Group Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)
Canaccord Genuity Group started coverage on Kymera Therapeutics in a report on Wednesday. They issued a 'buy' rating and a $106.00 target price for the company...
News Placeholder
UBS Group AG Buys 88,314 Shares of Kymera Therapeutics, Inc. $KYMR
UBS Group AG lifted its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 13.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and...
News Placeholder
Q2 EPS Estimate for Kymera Therapeutics Boosted by Analyst
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Stock analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for shares of Kymera Therapeutics in a report released on Monday, May 4th. HC Wainwright analyst A. Fein now expects that the company will post earnings pe...
News Placeholder
Jennison Associates LLC Decreases Stock Position in Kymera Therapeutics, Inc. $KYMR
Jennison Associates LLC lowered its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 51.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 496,665 shares of the company's sto...
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Upgraded to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
News Placeholder
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Posts Earnings Results, Beats Expectations By $0.18 EPS
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.71) earnings per share for the quarter, topping analysts' consensus...
News Placeholder
Kymera Therapeutics Q1 Earnings Call Highlights
Kymera Therapeutics (NASDAQ:KYMR) highlighted progress across its clinical-stage pipeline and provided a financial update during its first-quarter 2026 results call, with executives emphasizing...
News Placeholder
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of +20.40% and +211.90%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available